Dr David Lim speaks with Dr Gary Grohmann about Australia’s developing COVID-19 vaccination plan.
In this episode:
- Instead of efficacy, look at the secondary endpoints as vaccine data is being released
- Whilst the evidence for giving the AstraZeneca Oxford vaccine in patients over 65 yrs is small, it is still a reasonable option
- TGA is maintaining a very watchful eye on all new vaccines
- It is possible Australia will have 5 different vaccines available by the end of 2021
Host: Dr David Lim, GP
Guest: Dr Gary Grohmann, Virologist; Vaccine Manufacturing Expert; Former Director of Immunobiology and WHO ERL at the TGA, Office of Laboratories and Scientific Services
Total time: 27 mins
